Brad Stanfield: The ‘Toxic’ Hormone That Just Broke Every Obesity Record
Peer-Reviewed Research
Key Takeaways
- Retatrutide (triple-hormone agonist) achieved unprecedented weight loss (24-29% body weight) by activating GLP-1, GIP, and glucagon pathways.
- Monitor for dysesthesia (abnormal skin sensations) – 1 in 5 patients on the highest dose reported this novel side effect.
- Prioritize resistance training and protein intake to counteract muscle loss during rapid weight loss from these drugs.
- Be aware of discontinuation risks – 18% stopped due to excessive weight loss or side effects; weight regain likely if treatment stops.
Notable Quotes
“I never thought it was my father’s choice… obesity is biology, not just willpower.” – Ania Jastreboff
Bottom Line
While Retatrutide shows breakthrough efficacy for obesity, patients must actively preserve muscle mass and monitor for novel side effects like dysesthesia. Consult a doctor about risks vs. benefits before considering this treatment.
Explore More
- Brad Stanfield’s Full Protocol — supplements, dosages, and daily routine
- Compare All Protocols — side-by-side protocols
Watch the Full Video
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The research summaries presented here are based on published studies and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before making any changes to your health regimen.
Peer-reviewed health research, simplified. Early access findings, clinical trial alerts & regulatory news — delivered weekly.
No spam. Unsubscribe anytime. Powered by Beehiiv.
Related Research
From Our Research Network
Daily longevity researchZone2 Training
Exercise protocolsSleep Science
Sleep optimization
Part of the Evidence-Based Research Network